Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.41 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1852651 | 0.98 | ALDH1A1 (0.45) | ADORA3ADORA2AADORA1ALDH1A1CYP1A2 | |
| SCHEMBL14072191 | 0.87 | RPS6KA3 (0.47) | ADORA3ADORA2AADORA1ALDH1A1CYP1A2 | |
| Imidazole SCHEMBL7131590 | 0.84 | ADORA3 (0.36) | ADORA3ADORA2AADORA1ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7131591 | 0.84 | ADORA2A (0.37) | ADORA3ADORA2AADORA1ALDH1A1CYP1A2 | |
| SCHEMBL2028204 | 0.83 | CYP1A2 (0.44) | ADORA3ADORA2AADORA1ALDH1A1CYP1A2 | |
| SCHEMBL5891162 | 0.81 | NPSR1 (0.39) | ALDH1A1HPGDKDM4EHSD17B10TSHR | |
| SCHEMBL12582170 | 0.80 | CYP1A2 (0.42) | ADORA3ADORA2AADORA1ALDH1A1CYP1A2 | |
| SCHEMBL14072221 | 0.80 | RPS6KA3 (0.43) | ADORA3ADORA2AADORA1ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL5891157 | 0.79 | NPSR1 (0.38) | ALDH1A1HPGDKDM4EHSD17B10TSHR | |
| SCHEMBL24897834 | 0.78 | ALDH1A1 (0.40) | ADORA3ADORA2AADORA1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454526-B2 | Method for producing pyrrole-imidazole (poly)amide | KANEKA CORPORATION (JP) | 2025-10-28 | — | — | US | disclosed |
| WO-2025122764-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | Design Therapeutics, Inc. (US) | 2025-06-12 | — | — | WO | disclosed |
| EP-4539839-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | Design Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4539842-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | Design Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025076219-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2025076181-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-119677513-A | Methods and compounds for modulating genetic disease | 设计治疗公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119584961-A | Methods and compounds for modulating huntington's disease | 设计治疗公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4504339-A2 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-4460302-A2 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20080176859-A1 | HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS GMBH & CO. KG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176859-A1 | HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS GMBH & CO. KG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176859-A1 | HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS GMBH & CO. KG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-7348427-B2 | Antipathogenic benzamide compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348427-B2 | Antipathogenic benzamide compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | BAYER HEALTHCARE AG (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20070265240-A1 | Sequence Selective Pyrrole and Imidazole Polyamide Metallocomplexes | UNIVERSITY OF WESTERN SYDNEY (AU) | 2007-11-15 | — | — | US | disclosed |
| US-20070172826-A1 | Electrochemically active ligand for sequence-specific detection of double-stranded nucleic acid molecule | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-07-26 | — | — | US | disclosed |
| US-20070172826-A1 | Electrochemically active ligand for sequence-specific detection of double-stranded nucleic acid molecule | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-07-26 | — | — | US | disclosed |
| US-6566336-B1 | For therapy and prophylaxis of various gene- inducible diseases | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176859-A1 | HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES | TPMT, TYMP, PAICS | ADORA3 1451/4885ADORA2A 1139/4885ADORA1 2165/4885 |
| US-20070172826-A1 | Electrochemically active ligand for sequence-specific detection of double-stranded nucleic acid molecule | POLRMT, POLM, POLI | ADORA3 1585/4885ADORA2A 1075/4885ADORA1 834/4885 |
| US-20070265240-A1 | Sequence Selective Pyrrole and Imidazole Polyamide Metallocomplexes | POLRMT, MPI, PPIF | ADORA3 2695/4885ADORA2A 4072/4885ADORA1 3660/4885 |
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | IRF3, EIF2AK2, ZC3HAV1 | ADORA3 356/4885ADORA2A 590/4885ADORA1 394/4885 |
| US-12454526-B2 | Method for producing pyrrole-imidazole (poly)amide | DDC, PAM, AADAC | ADORA3 2203/4885ADORA2A 3532/4885ADORA1 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.